Compare EOG Resources Inc (EOG) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EOG Resources Inc vs Viatris Inc — how do they compare? EOG Resources Inc trades at $138.5 (market cap $73.22B), while Viatris Inc trades at $17.27 (market cap $19.44B). The key difference: EOG Resources Inc is far larger — about 3.8× Viatris Inc's market cap, and EOG Resources Inc pays the higher dividend (2.97%). Which is the better fit depends on your goals.
| EOG | VTRS | |
|---|---|---|
Market Cap | $73.22B | $19.44B |
Sector | Energy | Health |
52-Week High | $149.89 | $17.39 |
52-Week Low | $101.78 | $8.74 |
Enterprise Value | $77.68B | $31.65B |
Dividend Yield | 2.97% | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EOG Resources trades at $139.12, up 0.8% on the day, with a bullish technical outlook supported by moving averages and key resistance at $140. The company maintains strong profitability with a 23.39% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights EOG's valuation discount and operational strength, with a consensus price target of $156.40 suggesting 12% upside.
EOG presents a compelling investment case with solid fundamentals, consistent earnings beats, and positive analyst sentiment, though risks include oil price volatility and elevated capital expenditures. The stock's current valuation below historical averages offers a margin of safety for long-term investors seeking exposure to a high-quality energy producer.
Viatris (VTRS) trades at $17.215, up 5.55% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3 billion in 2025 but posted a net loss of $3.51 billion, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a decision expected by December 2026. Analyst consensus leans toward Hold, with a $20 price target suggesting modest upside from current levels.
The outlook for VTRS hinges on successful pipeline execution and debt management, offering value potential if biosimilar and specialty drug launches gain traction. Key risks include persistent negative margins, high debt levels, and competitive pressures in the generics market. Investors should weigh the company's cost-cutting efforts and product diversification against its profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About EOG Resources Inc
EOG Resources is an oil and gas producer with acreage in several U.S. shale plays, including the Permian Basin, the Eagle Ford, and the Bakken. At the end of 2021, it reported net proved reserves of 3.7 billion barrels of oil equivalent. Net production averaged 829 thousand barrels of oil equivalent per day in 2021 at a ratio of 72% oil and natural gas liquids and 28% natural gas.
Read more on EOG →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
